Background​

Since its inception in 2002, Corporate Responsibility (CR) has been a guiding principle for Alnylam, a leading, global biopharmaceutical company pioneering the discovery, development, and commercialization of RNAi therapeutics. In 2019, the company partnered with Cause Consulting to increase the sophistication of its CR approach and reporting, and develop a new signature social impact program.  Our strategic partnership with Alnylam continues to grow and evolve alongside the needs of the business and ever-changing ESG landscape. 

In 2020, Alnylam finalized and launched a new strategic CR Framework, governance structure, and theme—“Accepting Challenges to Improve the Health of Humanity”—to guide its work. This theme builds upon a commitment to tackle unprecedented and complex challenges, take courageous action, and use business as a force for good. The framework organized CR efforts into six interconnected, stakeholder-related focus areas: patients, science, employees, communities, planet, and governance, each led by an employee working group with direction from a cross-functional CR Committee reporting to the executive leadership team and board of directors. The use of six focused pillars helped the company  better understand and address more ESG business-related issues in addition to community focused activities.  

Alnylam’s first CR Summary 2020 provided investors, employees, and other stakeholders with a cross-enterprise view of the company’s CR and ESG priorities, accomplishments, practices, and future business and social commitments. This included sharing new information about diversity, equity and inclusion, environmental practices, patient support programs, and clinical trials, among other areas. 

During 2021, Alnylam performed its first CR Materiality Analysis to further identify the business-related issues most important to key internal and external stakeholders. The 2021 CR Report applied increased rigor throughout the development process, using  materiality to further focus content. It was aligned with SASB and GRI frameworks, and included  additional metrics, data, and targets. This report highlighted the launch of Alnylam Challengers, the company’s new signature social impact program focused on improving health equity by partnering with diverse social enterprises and non-profit organizations. The program tackles health inequalities, improves access to healthcare, and addresses social determinants of health (SDoH) in partnership with Acumen America. 

The 2022 CR Report celebrated the company’s 20th Anniversary and new CEO, and detailed efforts to further understand and mitigate its global environmental footprint, including greenhouse gas (GHG) emissions, water usage, and waste management. Alnylam reported significant strides in implementing its DE&I goals, including launching a formal US supplier diversity program and evolving its approach to clinical trial inclusion. The company also expanded its health equity initiatives, including extending the Alnylam Challengers program to international markets. 

The 2023 CR Report was guided by a Materiality Analysis refresh and featured advancements in patient access, employee engagement, and environmental stewardship. Additional highlights included the expansion of partnerships and strategies to support diversity and inclusion within clinical trials, and growth of the Alnylam Challengers program to include 5 new countries in which Alnylam has a local presence.  

Alnylam’s 2024 CR Report reflected a pivotal moment of growth as the company prepared for the early 2025 FDA approval of Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy (ATTR-CM).  The report reinforced the company’s commitments to DEI, brought to life and detailed third-party verification of its Scope 1, 2, and 3 greenhouse gas emissions and the transition to 100% renewable energy for its Alewife and Norton manufacturing facilities.  

During 2025, we initiated a regulatory compliance work stream, including CSRD, and a Double Materiality process, refreshed Alnylam Challengers and are gearing up for the 2025 CR Report to be launched in the spring of 2026.   

Learn More

• Alnylam’s 2020 Corporate Responsibility Summary
• Alnylam’s 2021 Corporate Responsibility Report
• Alnylam’s 2022 Corporate Responsibility Report
• Alnylam’s 2023 Corporate Responsibility Report
• Alnylam’s 2024 Corporate Responsibility Report
• Mini case on Alnylam Challengers, the company’s social impact signature program focused on improving health equity